GLP-1 Induces Barrier Protective Expression in Brunnerʼs Glands and Regulates Colonic Inflammation
The DOI matches its Crossref record; 62 of the 62 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Beneficial roles for glucagon-like peptide 1 (GLP-1)/GLP-1R signaling have recently been described in diseases, where low-grade inflammation is a common phenomenon. We investigated the effects of GLP-1 in Brunner's glands and duodenum with abundant expression of GLP-1 receptors, as well as GLP-1 effect on colonic inflammation. METHODS: RNA from Brunner's glands of GLP-1R knockout and wild-type mice were subjected to full transcriptome profiling. Array results were validated by quantitative reverse transcription polymerase chain reaction in wild-type mice and compared with samples from inflammatory bowel disease (IBD) patients and controls. In addition, we performed a detailed investigation of the effects of exogenous liraglutide dosing in a T-cell driven adoptive transfer (AdTr) colitis mouse model. RESULTS: Analyses of the Brunner's gland transcriptomes of GLP-1R knockout and wild-type mice identified 722 differentially expressed genes. Upregulated transcripts after GLP-1 dosing included IL-33, chemokine ligand 20 (CCL20), and mucin 5b. Biopsies from IBD patients and controls, as well as data from the AdTr model, showed deregulated expression of GLP-1R, CCL20, and IL-33 in colon. Circulating levels of GLP-1 were found to be increased in mice with colitis. Finally, the colonic cytokine levels and disease scores of the AdTr model indicated reduced levels of colonic inflammation in liraglutide-dosed animals. CONCLUSIONS: We demonstrate that IL-33, GLP-1R, and CCL20 are deregulated in human IBD, and that prophylactic treatment with 0.6 mg/kg liraglutide improves disease in AdTr colitis. In addition, GLP-1 receptor agonists upregulate IL-33, mucin 5b, and CCL20 in murine Brunner's glands. Taken together, our data indicate that GLP-1 receptor agonists affect gut homeostasis in both proximal and distal parts of the gut.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Histological scores, the colon weight/length ratio, and inflammatory cytokines/chemokines (such as CCL20, IL-33, and IL-22) were all considerably improved in a study by Bang-Berthelsen et al. when the GLP-1 analog liraglutide was used. 113”
From Anti-inflammatory role of glucagon-like peptide 1 receptor agonists and its clinical implications (2024) · cites this paper as [113]
In the citing paper
“Plasma GLP-1 is also elevated in mice with colitis induced by adoptive transfer of CD4+CD25– T cells (8), suggesting that a compromised intestinal barrier and translocation of intestinal microbes promote GLP-1 release.”
From Antiinflammatory actions of glucagon-like peptide-1–based therapies beyond metabolic benefits (2025) · cites this paper as [8]
In the citing paper
“Similarly, in a colitis model induced by adoptive transfer of CD4+CD25– T cells, daily 600 μg/kg liraglutide treatment for 35 days after transfer significantly reduced the colon weight-to-length ratio and improved colonic histopathology, preserving colonic crypt structure and reducing leukocyte infiltration (8).”
From Antiinflammatory actions of glucagon-like peptide-1–based therapies beyond metabolic benefits (2025) · cites this paper as [8]
In the citing paper
“A single dose of 1 mg/kg exenatide or 500 μg/kg liraglutide induced Il33, Muc5b, and Ccl20 expression in Brunner’s glands of control mice but not in Glp1r–/– mice (8).”
From Antiinflammatory actions of glucagon-like peptide-1–based therapies beyond metabolic benefits (2025) · cites this paper as [8]
Citations
Cites
Analysis of Relative Gene Expression Data Using Real-Time Quantitative PCR and the 2−ΔΔCT Method
Livak, K. J., & Schmittgen, T. D. (2001) · Methods · doi:10.1006/meth.2001.1262 · Cited by 180,860 · cited 1×
“The comparative CT method was used to analyze the data.(30) The results are shown as2DCT-values or fold change.”
MethodThe Physiology of Glucagon-like Peptide 1
Holst, J. J. (2007) · Physiological Reviews · doi:10.1152/physrev.00034.2006 · Cited by 3,371 · cited 2×
“lation of the blood glucose levels by stimulating insulin expression and secretion and lowering glucagon secretion.(5) GLP-1 also suppresses energy intake, which subsequently leads to weight loss.”
BackgroundMethodThe biology of incretin hormones
Drucker, D. J. (2006) · Cell Metabolism · doi:10.1016/j.cmet.2006.01.004 · Cited by 2,210 · cited 1×
“Mature glucagon, glucagon-like peptide 1 (GLP-1) and GLP-2, as well as glicentin, oxyntomodulin are formed as the result of tissue-specific posttranslational processing of proglucagon (PG).(1) The incretin hormone GLP-1 is secreted when the L cells sense nutrients.”
BackgroundVan der Sluis, M., De Koning, B. A. E., De Bruijn, A. C. J. M., Velcich, A., Meijerink, J. P. P., Van Goudoever, J. B., Büller, H. A., Dekker, J., Van Seuningen, I., Renes, I. B., et al. (2006) · Gastroenterology · doi:10.1053/j.gastro.2006.04.020 · Cited by 1,684 · cited 1×
“Mucins play an important role in the intestinal function in mice, in both health and disease.(49,50) MUC5B has previously been associated with functions in the lungs where MUC5B KO mice are highly susceptible to airway infections.”
BackgroundPharmacology, physiology, and mechanisms of incretin hormone action.
Campbell, J. E., & Drucker, D. J. (2013) · Cell Metabolism · doi:10.1016/j.cmet.2013.04.008 · Cited by 1,500 · cited 1×
“Native GLP-1 and -2 hormones are rapidly degraded in transit to the bloodstream by dipeptidyl peptidase 4 (DPP-4).(3,4) GLP-1 has been shown to play a central role in regu-”
BackgroundGlucagon-like peptide 1 promotes satiety and suppresses energy intake in humans.
Flint, A., Raben, A., Astrup, A., & Holst, J. J. (1998) · Journal of Clinical Investigation · doi:10.1172/jci990 · Cited by 1,402 · cited 1×
“GLP-1 also suppresses energy intake, which subsequently leads to weight loss.(6) Recent reports in mice focus on the local role of GLP-1 and GLP-2 receptors in the GI tract where GLP-1 and GLP-2 have”
BackgroundEllingsgaard, H., Hauselmann, I., Schuler, B., Habib, A. M., Baggio, L. L., Meier, D. T., Eppler, E., Bouzakri, K., Wueest, S., Muller, Y. D., et al. (2011) · Nature Medicine · doi:10.1038/nm.2513 · Cited by 922 · cited 1×
“kines such as IL-6 induces secretion of GLP-1 indicating a link between inflammation and GLP-1 expression.(18) It has also been shown in vitro that GLP-1R agonist has an antiapoptotic effect on islets exposed to proinflammatory cytokines,(59) suggesting that the GLP-1R/GLP-1 axis is modulated by inflammation.”
BackgroundDeacon, C. F., Nauck, M. A., Toft-Nielsen, M., Pridal, L., Willms, B., & Holst, J. J. (1995) · Diabetes · doi:10.2337/diab.44.9.1126 · Cited by 878 · cited 1×
“Native GLP-1 and -2 hormones are rapidly degraded in transit to the bloodstream by dipeptidyl peptidase 4 (DPP-4).(3,4) GLP-1 has been shown to play a central role in regu-”
BackgroundPyke, C., Heller, R. S., Kirk, R. K., Ørskov, C., Reedtz-Runge, S., Kaastrup, P., Hvelplund, A., Bardram, L., Calatayud, D., & Knudsen, L. B. (2014) · Endocrinology · doi:10.1210/en.2013-1934 · Cited by 876 · cited 2×
“After cutting, the tissue was stained with DAPI together with staining for the GLP-1R with an in-house generated mouse antihuman MAb (3F52) directed against GLP-1R extracellular domain.(28)”
MethodSelf-citationMucosal healing in inflammatory bowel diseases: a systematic review
Neurath, M. F., & Travis, S. P. L. (2012) · Gut · doi:10.1136/gutjnl-2012-302830 · Cited by 810 · cited 4×
“In addition, DPP-4 inhibitors have been proposed as therapeutic agents for ameliorating inflammatory processes in immunologically mediated diseases such as IBD.(12,15) The role of GLP-1/GLP-1R signaling in human IBD is largely unknown.”
BackgroundInfluential
Research works printed but not linked: 3
- Damholt, 1998, Endocrinology, 139, 2085, 10.1210/endo.139.4.5921 · doi:10.1210/endo.139.4.5921 · Paper page
- Wilken, 1991, Diabetologia, 42, A196
- Flemström, 1999, Am J Physiol, 277, G375
Cited by
The Discovery and Development of Liraglutide and Semaglutide
Knudsen, L. B., & Lau, J. (2019) · Frontiers in Endocrinology · doi:10.3389/fendo.2019.00155 · Cited by 970
Self-citationRakipovski, G., Rolin, B., Nøhr, J., Klewe, I., Frederiksen, K. S., Augustin, R., Hecksher-Sørensen, J., Ingvorsen, C., Polex-Wolf, J., & Knudsen, L. B. (2018) · JACC: Basic to Translational Science · doi:10.1016/j.jacbts.2018.09.004 · Cited by 509
“Recently, liraglutide has been shown to upregulate genes encoding mucins and other barrier protective molecules including IL-33 in Brunner glands of mice (40).”
BackgroundSelf-citationAnti-inflammatory role of glucagon-like peptide 1 receptor agonists and its clinical implications
Alharbi, S. H. (2024) · Therapeutic Advances in Endocrinology and Metabolism · doi:10.1177/20420188231222367 · Cited by 358
“113 Patients with active UC and CD had higher amounts of bioactive GLP-2 than healthy controls, according to a study by Xiao et al. 114 However, Schmidt et al. found no difference in meal-stimulated GLP-2 plasma or tissue concentrations between IBD and non-IBD individuals.”
ResultRevisiting the Complexity of GLP-1 Action from Sites of Synthesis to Receptor Activation
McLean, B. A., Wong, C. K., Campbell, J. E., Hodson, D. J., Trapp, S., & Drucker, D. J. (2021) · Endocrine Reviews · doi:10.1210/endrev/bnaa032 · Cited by 289
Worthington, J. J., Reimann, F., & Gribble, F. M. (2018) · Mucosal Immunology · doi:10.1038/mi.2017.73 · Cited by 262
Metadata
- Authors
- Bang-Berthelsen, C. H., Holm, T. L., Pyke, C., Simonsen, L., Søkilde, R., Pociot, F., Heller, R. S., Folkersen, L., Kvist, P. H., Jackerott, M., Fleckner, J., Vilién, M., Knudsen, L. B., Heding, A., & Frederiksen, K. S.
- Affiliations
- Novo Nordisk (Denmark) (DK)
- University of Copenhagen (DK)
- Corresponding author
- Holm, Thomas L.
- ORCID
- Venue
- Inflammatory Bowel Diseases
- Publisher
- Oxford University Press (OUP)
- Published
- 2016-09
- Volume
- 22
- Issue
- 9
- Pages
- 2078-2097
- ISSN
- 1078-0998 (ISSN-L)
- OpenAlex
- W2507524244
- Cited by
- 111
- References
- 62
- Citations by year
- 2026: 15 · 2025: 19 · 2024: 14 · 2023: 6 · 2022: 18 · 2021: 11 · 2020: 10 · 2019: 7 · 2018: 4 · 2017: 7
- FWCI
- 4.85
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Inflammatory Bowel Diseases (publishedVersion)
- PubMed (publishedVersion)
- Lund University Publications (Lund University) (submittedVersion)
- Research at the University of Copenhagen (University of Copenhagen) (submittedVersion)
- Technical University of Denmark, DTU Orbit (Technical University of Denmark, DTU) (submittedVersion)
- Topics
- Health Sciences › Medicine › Gastroenterology › Inflammatory Bowel Disease
- Life Sciences › Immunology and Microbiology › Immunology › IL-33, ST2, and ILC Pathways
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Keywords
- glucagon-like peptide-1, GLP-1 receptor
- MeSH terms
- Interleukin-33, Glucagon-Like Peptide-1 Receptor, Liraglutide, Glucagon-Like Peptide-1 Receptor Agonists, Adolescent, Adult, Aged, Aged, 80 and over, Animals, Brunner Glands, Colitis, Colon, Female, Humans, Inflammation, Male, Mice, Inbred C57BL, Middle Aged, RNA, Messenger, Inflammatory Bowel Diseases, Gene Expression, Mice, Knockout, Mice, Chemokine CCL20, Mucin-5B, Young Adult
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: GLP-1 Induces Barrier Protective Expression in Brunnerʼs Glands and Regulates Colonic Inflammation. https://app.cochat.ai/papers/10.1097/mib.0000000000000847
- The paper
- Bang-Berthelsen, C. H., Holm, T. L., Pyke, C., Simonsen, L., Søkilde, R., Pociot, F., Heller, R. S., Folkersen, L., Kvist, P. H., Jackerott, M., Fleckner, J., Vilién, M., Knudsen, L. B., Heding, A., & Frederiksen, K. S. (2016). GLP-1 Induces Barrier Protective Expression in Brunnerʼs Glands and Regulates Colonic Inflammation. Inflammatory Bowel Diseases. https://doi.org/10.1097/mib.0000000000000847
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.